AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2019
36
Period ended Dec 31, 2019
Change on a year earlier
-79.8%
178 in FY2018
History
5 years
Since FY2015
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 36 | -79.8% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 178 | -77.3% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 784 | -48.5% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 1,522 | -7.1% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 1,639 | – | Form 10-K (filed 2017-02-17) ↗ |
Breakdown
What makes up viekira (ombitasvir/paritaprevir/ritonavir) [legacy through fy20q1] — worldwide net revenues ($m)
Cite this data
StockData. (2026). AbbVie Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M), annual FY2015–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/viekira_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.